about
Passenger deletions generate therapeutic vulnerabilities in cancerFailure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroCurrent Management Strategies in Breast Cancer by Targeting Key Altered Molecular PlayersThe role of PARP in DNA repair and its therapeutic exploitationEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesSingle cell resolution in vivo imaging of DNA damage following PARP inhibitionTargeting DNA repair pathways for cancer treatment: what's new?A role of intracellular mono-ADP-ribosylation in cancer biology.Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.Hereditary breast cancer: clinical, pathological and molecular characteristics.Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cellsNanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity.Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoTargeting angiogenesis in metastatic breast cancerCross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1α, autophagy and ketone body productionMechanisms and insights into drug resistance in cancerThe role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapyPARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cellsOncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.Sex differences in stroke therapiesPhysiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlationmiR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.PARP inhibitors in cancer therapy: an update.Beyond DNA repair, the immunological role of PARP-1 and its siblings.PARP inhibitors: polypharmacology versus selective inhibition.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.Human DNA ligases: a comprehensive new look for cancer therapy.Shotgun proteomics of archival triple-negative breast cancer samples.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicksTargeting the fanconi anemia pathway to identify tailored anticancer therapeutics.
P2860
Q24598469-5C350848-E5E3-46D1-B5CA-171650F4A627Q24615499-4E24114F-B5BB-46F5-ABA1-3DD9D7291997Q26765877-9148F549-993B-4705-8242-3FF50A813395Q27002399-6FDAF935-59B0-406B-A084-FBE376E17F06Q29147555-9A2ECA25-5479-413B-9CE4-230562144146Q30570945-7A135910-C04D-4FB5-9352-115BFFBDC42DQ30650918-96AF8DE9-21F1-490D-917B-5F1C6223362AQ34015040-80CE6F00-F0EA-4544-A0F7-8F05426A6A13Q34036347-1D6C297F-ACA6-4649-AE94-E22EBC6D57B4Q34210627-75797F26-A156-4FA7-8778-294A27E4143FQ34425230-CBB07A99-D5A9-4E03-9A3A-2B83CB970218Q34978267-04C6E97F-30E4-425F-BC05-CE9E42E67352Q35534276-6E060FFD-694B-4450-8B7C-274B1098E971Q35684568-8ED4C056-5896-4EB9-92E1-96A7E2D4CE28Q35879098-5450C4E7-FE68-4885-85B8-886E82D2B0D9Q36160278-27B37C24-34F8-4E04-AA6A-75267CF7E116Q36182795-71E5D22D-F36B-46B0-A84C-89CAE53239A7Q36195450-C36E6A1D-7E45-47C7-941E-C042943E13A4Q36238650-310E81D1-FB7A-4C01-B21C-ABF084BAF137Q36472238-A3C01293-140D-4072-A7E3-91CABB5ACD1EQ36682301-7727A4C7-A4BC-4493-87A9-89938FEEE7B8Q36689932-7CBAF0E2-B68A-473F-84D1-6B774F60F590Q36901517-43BED4D5-4DBC-49C8-9C7C-9B67CEAB2FDAQ37018223-307DBE3C-C57E-442C-95DD-B9CB30626555Q37166313-B3B2D2E9-6910-4939-BB42-3D8306D23798Q37445950-939A702F-8920-4288-8D35-228AF3D5B6D1Q37572883-8F2E3ECC-D15F-4AD3-B58D-92F0BF613439Q37697004-186370B4-0381-40DA-8E80-7FD8CC205389Q38078993-BDB1EDF8-E4F4-49E3-9958-9B2708423347Q38089268-D12DB9EC-7CC4-4800-990C-D64959439D6DQ38100299-D611F813-6768-408D-A09C-D7637BB3CCD5Q38129725-5D2EC0CA-AFB7-40B4-94C9-EF05332ABFFEQ38130159-2B3F04A6-DBA0-4A80-AD28-BD728ECAA79FQ38398043-6CB768F9-2F6D-4218-A083-50F20F45AEA6Q38596368-8AFFF96D-4537-4158-8806-E035EFB34BE6Q38888022-18CC812A-38F9-439D-883B-18552BFAC721Q39437808-C1907E0F-7A8B-4B97-B419-915E8358627DQ41527706-545B74AD-95ED-4DD5-AEF3-CD4A4ECF6A72Q41834722-DE9CE24C-F24E-481E-8C85-F9AC28574497Q42055866-B8C65BDD-CC01-4735-A7D4-E5DA96693F85
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
PARP inhibitors stumble in breast cancer
@ast
PARP inhibitors stumble in breast cancer
@en
PARP inhibitors stumble in breast cancer
@nl
type
label
PARP inhibitors stumble in breast cancer
@ast
PARP inhibitors stumble in breast cancer
@en
PARP inhibitors stumble in breast cancer
@nl
prefLabel
PARP inhibitors stumble in breast cancer
@ast
PARP inhibitors stumble in breast cancer
@en
PARP inhibitors stumble in breast cancer
@nl
P356
P1433
P1476
PARP inhibitors stumble in breast cancer
@en
P2093
Malini Guha
P2888
P356
10.1038/NBT0511-373
P407
P577
2011-05-01T00:00:00Z